GLA and Fabry disease: The accumulation of clinical trial and real world evidence over the last 20 years has shown that enzyme replacement therapy (ERT) via the lifelong intravenous infusions of gene activated agalsidase alfa (Schiffmann et al., 2001) or recombinant agalsidase beta (Eng et al., 2001) every other week is safe and clinically and biologically effective in patients with FD (Wanner et al., 2018; Spada et al., 2019; Germain et al., 2022; Burlina et al., 2023; Wanner et al., 2023).